Bank of New Hampshire Sells 1,365 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Bank of New Hampshire decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 49.4% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 1,400 shares of the biopharmaceutical company’s stock after selling 1,365 shares during the quarter. Bank of New Hampshire’s holdings in Gilead Sciences were worth $157,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Annis Gardner Whiting Capital Advisors LLC raised its stake in Gilead Sciences by 158.8% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 216 shares during the period. Newbridge Financial Services Group Inc. bought a new stake in Gilead Sciences in the fourth quarter valued at approximately $33,000. Morton Brown Family Wealth LLC bought a new stake in Gilead Sciences in the fourth quarter valued at approximately $35,000. Whipplewood Advisors LLC bought a new stake in Gilead Sciences in the fourth quarter valued at approximately $35,000. Finally, Synergy Investment Management LLC bought a new stake in Gilead Sciences in the fourth quarter valued at approximately $40,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $112.46 on Monday. The stock’s fifty day moving average price is $105.39 and its two-hundred day moving average price is $101.64. Gilead Sciences, Inc. has a one year low of $62.69 and a one year high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The firm has a market cap of $139.89 billion, a PE ratio of 303.95, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same quarter last year, the company earned ($1.32) EPS. The company’s revenue was down .3% on a year-over-year basis. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.81%. Gilead Sciences’s dividend payout ratio (DPR) is currently 66.53%.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Friday, May 30th. The stock was sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the completion of the transaction, the chief executive officer now owns 620,268 shares of the company’s stock, valued at approximately $68,489,992.56. The trade was a 1.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider now directly owns 121,152 shares of the company’s stock, valued at $13,026,263.04. This trade represents a 18.77% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 43,000 shares of company stock valued at $4,630,310. Corporate insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on GILD. Royal Bank of Canada upped their price objective on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. The Goldman Sachs Group increased their target price on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Morgan Stanley increased their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, April 25th. Finally, Cantor Fitzgerald began coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 target price on the stock. Nine research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.